Medication nonadherence remains a formidable clinical challenge in transplantation medicine, directly correlating with the incidence of allograft rejection and subsequent morbidity. Adolescents and young adults are disproportionately affected, often struggling with complex immunosuppressive regimens required to prevent rejection. Traditional detection methods rely heavily on patient self-reporting or sporadic clinical assessments, both of which are prone to bias and oversight. The MLVI surmounts these limitations by quantifying fluctuations in immunosuppressant blood concentrations extracted from routine lab draws, thus providing an objective, continuously updated marker of adherence consistency.

The study encompassed 13 leading pediatric transplant centers across the United States and Canada, screening over 3,000 liver transplant recipients’ medical records. A subset of 148 high-risk patients, identified through elevated MLVI scores indicating inconsistent medication intake, were randomized to receive either standard care or a comprehensive two-year telehealth-based behavioral intervention. This innovative intervention utilized regular, remote engagement with behavioral specialists trained to reinforce adherence strategies and support patient self-management remotely, a particularly pivotal adaptation during the COVID-19 pandemic’s disruption of traditional in-person care.

Although the trial did not achieve statistical significance on the composite primary endpoint—which included rejection episodes, re-transplantation, and patient withdrawal—this was attributed to unexpectedly low rejection rates in both the intervention and control arms. Notably, recipients undergoing the remote behavioral intervention experienced roughly half as many rejection-related events and instances of re-transplantation relative to those in the standard care group. This signals a clinically meaningful impact akin to significant risk reduction, underscoring the utility of integrating MLVI-guided interventions into routine post-transplant care.

Beyond the study’s interventional efficacy, a compelling secondary finding was the noticeable reduction in overall rejection incidences associated with systematic MLVI implementation itself. Deployment of this risk marker as part of routine clinical workflows appeared to recalibrate clinician vigilance and patient management strategies effectively, driving digital medicine toward a more proactive, preemptive paradigm. This represents a paradigm shift from traditional reactive post-rejection treatment models to anticipatory, preventive care grounded in real-time data analytics.

In elucidating the clinical implications, Dr. Eyal Shemesh, lead investigator and behavioral health chief at Mount Sinai Kravis Children’s Hospital, emphasized the profound potential of harnessing extant EHR data in identifying nonadherence before it culminates in irreversible graft damage. This methodology enables focused allocation of clinical resources toward those patients most at risk, potentially mitigating adverse outcomes and associated healthcare costs through early behavioral interventions.

The underlying mechanistic rationale of the MLVI involves assessing intra-patient variability in immunosuppressant blood levels, primarily tacrolimus—a calcineurin inhibitor with a narrow therapeutic index vital for transplant survival. High MLVI values reflect erratic drug intake patterns, which compromise steady-state pharmacokinetics essential for consistent immunosuppression. This bioinformatics approach quantifies variability statistics, facilitating clinician recognition of subtle, yet clinically consequential lapses in adherence previously undetectable through conventional means.

Remote intervention strategies adopted in the study capitalized on telemedicine’s scalability and patient-centered design, utilizing frequent virtual check-ins to monitor, educate, and motivate adolescent transplant recipients. This framework not only fostered sustained engagement over two years but also offered a flexible alternative amidst pandemic-induced restrictions, showcasing telehealth’s integral role in contemporary chronic disease management and its potential to enhance access and adherence among geographically diverse populations.

Dr. Benjamin L. Shneider of Texas Children’s, senior author and leading gastroenterologist, highlighted the broader applicability of these findings beyond transplantation, suggesting that integrating biomarkers like MLVI could revolutionize care paradigms for myriad chronic conditions where adherence is paramount. The study advocates for embedding such objective adherence metrics within EHR platforms, enabling clinicians to harness precision medicine tools capable of individualized risk stratification and tailored intervention deployment.

Importantly, the study also delineates future avenues for investigation to optimize resource utilization and cost-effectiveness of MLVI-guided behavioral programs. While efficacy signals are positive, defining precise thresholds for intervention initiation, intervention intensity, and long-term sustainability require further study. Additionally, expanding the MLVI concept to encompass other organ transplant types and immunosuppressive agents could broaden the tool’s impact across transplant medicine.

The research was conducted within the multidisciplinary environment of the Texas Children’s Research Institute, leveraging cross-specialty collaboration to translate laboratory insights into tangible clinical strategies. Funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the National Institutes of Health (NIH), this project exemplifies how integrating data science with clinical expertise catalyzes breakthroughs in patient care.

In conclusion, this study marks a significant advance in transplant medicine’s ongoing quest to mitigate rejection through early detection of medication nonadherence. By employing an EHR-based biomarker coupled with remote, behaviorally informed interventions, clinicians can pivot toward a model that prioritizes prevention over treatment of rejection episodes. This shift harbors profound implications for improving long-term transplant survival, reducing hospitalizations, and enhancing quality of life for adolescent and young adult transplant recipients worldwide.

Subject of Research: Medication nonadherence detection and intervention in adolescent liver transplant recipients using an EHR-based biomarker (MLVI).

Article Title: A remote intervention to improve medication nonadherence guided by a marker of risk derived from the electronic health records of adolescent transplant recipients.

News Publication Date: June 15, 2026

Web References:
American Journal of Transplantation article
Texas Children’s Hospital
Mount Sinai Health System Facebook
Mount Sinai Health System Instagram
Mount Sinai Health System LinkedIn
Mount Sinai Health System Twitter (X)
Mount Sinai Health System YouTube

References: American Journal of Transplantation, AJT1253, May 27, 2026

Keywords: Medication Level Variability Index, MLVI, medication nonadherence, liver transplantation, organ rejection, adolescent transplant recipients, electronic health records, telehealth intervention, immunosuppressant monitoring, behavioral health, pediatric transplantation, remote patient monitoring

The study encompassed 13 pediatric transplant centers across the United States and Canada, reviewing over 3,000 liver transplant recipients’ electronic health data. From this vast dataset, 148 adolescents and young adults were identified as high-risk for organ rejection based on their MLVI scores. Participants were then randomized to receive either standard post-transplant care or a two-year, telehealth-based behavioral intervention aimed at improving medication adherence. This remote intervention involved regular check-ins and support from trained specialists, providing a scalable and patient-centered approach to healthcare delivery.

While the primary endpoint—a composite measure assessing rejection incidents, need for retransplantation, and withdrawal of consent—did not reach statistical significance, this outcome was largely due to unexpectedly low rejection rates in both treatment groups. Notably, the group receiving behavioral intervention exhibited roughly half the number of rejection-related events compared to those under standard care. These findings underscore the potential clinical benefit of combining MLVI-guided risk stratification with proactive remote intervention to reduce organ rejection, minimizing severe complications before they arise.

Traditionally, transplant clinicians have struggled to objectively identify patients who inconsistently take their immunosuppressant medications, due to the reliance on self-reported adherence or expensive and laborious monitoring methods. MLVI innovates on these fronts by using intra-patient variability in drug blood concentrations—collected routinely during follow-up laboratory assessments—as an objective, quantifiable metric. Because transplant recipients undergo frequent therapeutic drug monitoring, MLVI harnesses existing clinical data streams, facilitating risk assessment without additional burden or cost.

Eyal Shemesh, MD, Chief of Behavioral and Developmental Health at Mount Sinai Kravis Children’s Hospital and lead investigator of the study, highlighted the profound shift this technology enables: “Our findings show that we can detect early nonadherence by using data already embedded in electronic health records, allowing clinicians to intervene proactively, a strategy years ahead of reactive treatment post-rejection.” Dr. Shemesh’s dual expertise in pediatrics and psychiatry informs a nuanced understanding of adolescent health behaviors in the transplant context, emphasizing the study’s translational potential.

Adolescents and young adults represent a particularly vulnerable demographic in transplant care due to developmental, psychological, and social challenges that affect consistent medication use. The MLVI marker and subsequent remote intervention address these challenges by tailoring care management to individual risk profiles. This precision medicine approach not only improves outcomes but could also alleviate healthcare system burdens by reducing hospitalizations and retransplant rates, thereby preserving scarce donor organs and enhancing quality of life for recipients.

An integral component of the study’s success was its innovative telehealth platform, which maintained continuous engagement with patients through the COVID-19 pandemic, a period that intensified healthcare access disparities. Through virtual check-ins, behavioral coaching, and personalized support, the intervention demonstrated that even high-risk patients could achieve sustained adherence. This model suggests new avenues for scalable, resource-efficient care delivery, adaptable to broad clinical settings beyond transplantation.

Benjamin L. Shneider, MD, senior author and Chief of Gastroenterology at Texas Children’s Hospital, emphasized the practical implications: “This study paves the way for early detection and intervention for nonadherence before life-threatening rejection occurs. The use of MLVI combined with remote behavioral support offers a blueprint to optimize pediatric liver transplant outcomes and may revolutionize chronic disease management for children and families worldwide.”

George Mazariegos, MD, Chair of the Starzl Network for Excellence in Pediatric Transplantation, reinforced the broader impact, noting that early behavioral correction informed by objective risk markers could reshape lifelong care strategies for transplant recipients. His position at a leading pediatric transplant center amplifies the significance of incorporating MLVI into clinical workflows to systematically improve patient trajectories.

Despite the encouraging clinical trends, researchers acknowledge that the intervention’s efficacy, efficiency, and cost-effectiveness require further rigorous evaluation. Nonetheless, the study provides compelling evidence supporting the integration of MLVI into routine post-transplant care protocols, moving clinical practice toward preemptive, data-driven management rather than reliance on reactive measures after complications arise.

This novel application of electronic health record data analytics marks a critical advance in personalized transplant medicine. By capturing medication adherence patterns objectively and remotely intervening to support behavioral change, healthcare teams can stabilize graft function, reduce morbidity, and extend graft survival. The convergence of routine lab data, telehealth innovation, and behavioral science exemplifies the future of precision medicine in complex chronic conditions.

Funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health, this research underscores the power of collaborative, multicenter efforts to tackle persistent challenges in transplant medicine. As healthcare systems increasingly digitize, leveraging EHR-derived metrics like MLVI for proactive patient management may extend well beyond transplantation to improve outcomes across numerous chronic illnesses.

In conclusion, this study establishes MLVI as a transformative, objective risk stratification tool and confirms the feasibility and promise of remote behavioral interventions in improving medication adherence among adolescent transplant patients. This paradigm shift from reaction to prevention has the potential to revolutionize transplant care and pave the way for broader applications in chronic disease management, illustrating the profound impact of integrating electronic health records with innovative clinical strategies.

Subject of Research:
Medication nonadherence and risk stratification in adolescent liver transplant recipients using an EHR-derived marker to predict and prevent organ rejection.

Article Title:
A remote intervention to improve medication nonadherence guided by a marker of risk derived from the electronic health records of adolescent transplant recipients.

News Publication Date:
June 15, 2026

Web References:
https://www.mountsinai.org
https://www.texaschildrens.org
https://doi.org/10.1016/j.ajt.2026.04.03

References:
American Journal of Transplantation, Article DOI: 10.1016/j.ajt.2026.04.03, Published May 27, 2026

Keywords:
Transplantation, Medication adherence, Electronic health records, Adolescents, Liver transplantation, Immunosuppressant variability, Remote behavioral intervention, Telehealth, Chronic disease management, Organ rejection prevention, Pediatric transplant care, Precision medicine